Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.
| Revenue (TTM) | $11.61B |
| Gross Profit (TTM) | $3.88B |
| EBITDA | $1.83B |
| Operating Margin | 9.88% |
| Return on Equity | -9.04% |
| Return on Assets | 2.71% |
| Revenue/Share (TTM) | $22.54 |
| Book Value | $12.57 |
| Price-to-Book | 2.04 |
| Price-to-Sales (TTM) | 1.15 |
| EV/Revenue | 1.731 |
| EV/EBITDA | 18.86 |
| Quarterly Earnings Growth (YoY) | 36.80% |
| Quarterly Revenue Growth (YoY) | 5.00% |
| Shares Outstanding | $517.35M |
| Float | $514.76M |
| % Insiders | 0.34% |
| % Institutions | 109.46% |
Volatility is currently expanding
Baxter International NYSE: BAX raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execution and strong free cash flow generation.
BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.69 per share a year ago.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger founda.
Baxter International Inc. BAX is scheduled to release third-quarter 2026 results on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BAX and any ticker you trade — then tracks every position and per-strategy win rate.
